Rozel Denosumab 60 mg Injection

Q: How should Rozel Denosumab 60 mg Injection be administered?

A: Rozel should be given as a subcutaneous injection, typically in the upper arm, thigh, or abdomen. It is administered by a healthcare professional every six months as a single dose of 60 mg, using the pre-filled syringe provided.

Q: What is the primary benefit of using Rozel Denosumab Injection?

A: The main benefit of Rozel is the reduction of bone loss and the increase in bone strength, which significantly lowers the risk of osteoporotic fractures in high-risk individuals, including postmenopausal women and patients with bone loss due to hormone ablation therapy in cancer.

Q: When is Rozel Denosumab recommended for patients?

A: Rozel Denosumab is recommended for adults, particularly postmenopausal women, and patients with significant bone loss caused by cancer treatments, who are at high risk of fracture and have not responded to alternative osteoporosis therapies.

Q: What precautions should be taken while using Rozel?

A: Serum calcium levels should be closely monitored before and during treatment. Patients with hypocalcemia or known hypersensitivity to Denosumab should not use Rozel. Special care is required for individuals with renal impairment, and any new symptoms should be reported to the treating physician promptly.

Q: Where should Rozel Denosumab be stored?

A: Rozel should be kept in a cool, dry location away from direct heat or sunlight, and must be out of reach of children. Always check the packaging for any changes in color or clarity before use, and discard if the solution appears cloudy or contains particulates.

Q: What is the shelf life and packaging of Rozel Denosumab Injection?

A: Rozel has a shelf life of 24 months and is supplied as a pre-filled single-use syringe containing 1 ml of clear to slightly yellow solution, with each box containing one syringe to ensure precise dosing and minimal wastage.